{
  "source": "PA-Notification-Ctexli.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1481-1\nProgram Prior Authorization/Notification\nMedication Ctexli™ (chenodiol)\nP&T Approval Date 6/2025\nEffective Date 9/1/2025\n1. Background:\nCtexli (chenodiol) is a bile acid indicated for treatment of cerebrotendinous xanthomatosis\n(CTX) in adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Ctexli will be approved based on the following criterion:\na. Diagnosis of cerebrotendinous xanthomatosis (cholestanol storage disease)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Ctexli will be approved based on the following criterion:\na. Documentation of positive clinical response to Ctexli therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. Reference:\n1. Ctexli [package insert]. Foster City, CA: Mirum Pharmaceuticals, Inc.; February 2025.\nProgram Prior Authorization/Notification - Ctexli (chenodiol)\nChange Control\n6/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}